EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

MicroRNA-138-2-3p inhibits cell migration, invasion and EMT process in non-small-cell lung cancer by targeting antizyme inhibitor 1

Ang Cai, Zhuocui She, Jun Lv, Xiaokang Zhou, Miaomiao Xie

Revista de Investigación Clínica · 2026

DOI: 10.1016/j.ric.2025.100032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista de Investigación Clínica, 2026. Verfasst von Ang Cai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Wuhan Hospital of Traditional Chinese Medicine, Wuhan 430014, China. Hauptthemen laut MEDLINE: MicroRNAs, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Non-small cell lung cancer (NSCLC) represents over 85% of lung cancer diagnoses and is a leading cause of cancer-related mortality worldwide. The study investigated the role of microRNA-138-2-3p (miR-138-2-3p) in regulating NSCLC cell migration, invasion, and epithelial-mesenchymal transition (EMT). METHODS: MiR-138-2-3p and target gene expression were measured by RT-qPCR or western blotting. Cell viability, migration, and invasion were analyzed using cell counting kit-8, wound healing, and Transwell assays. RNA pull-down assays were performed to determine the enrichment of antizyme inhibitor 1 (AZIN1) by biotinylated miR-138-2-3p, while luciferase reporter assay confirmed direct binding between miR-138-2-3p and AZIN1. RESULTS: MiR-138-2-3p was significantly downregulated in NSCLC cells and tissues. Its overexpression markedly suppressed NSCLC cell viability, migration, invasion, and epithelial-mesenchymal transition. AZIN1 was upregulated in NSCLC cells and tissues and directly targeted by miR-138-2-3p via binding to its 3'untranslated region, showing a negative correlation in expression. Moreover, AZIN1 overexpression reversed the suppressive effects of miR-138-2-3p on the malignant phenotype in NSCLC cells. Notably, bioinformatics analysis shows that lung adenocarcinoma patients with high AZIN1 expression exhibit significantly worse overall survival than those with low AZIN1 expression. CONCLUSION: The results suggest that miR-138-2-3p inhibits the malignant phenotype of NSCLC cells by targeting AZIN1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansEpithelial-Mesenchymal TransitionCell MovementNeoplasm InvasivenessCell Line, TumorGene Expression Regulation, NeoplasticDown-RegulationCell SurvivalUp-Regulation

Stichwörter der Autor:innen

Antizyme inhibitor 1Epithelial–mesenchymal transitionNon-small-cell lung cancermiR-138-2-3p

Substanzen

MicroRNAsMIRN138 microRNA, human

Autor:innen und Institutionen

  • Department of Oncology, Wuhan Hospital of Traditional Chinese Medicine, Wuhan 430014, China.
  • Department of Oncology, Wuhan Hospital of Traditional Chinese Medicine, Wuhan 430014, China. Electronic address: zxk9472@163.com.
  • Department of Oncology, Wuhan Hospital of Traditional Chinese Medicine, Wuhan 430014, China. Electronic address: 149509509@qq.com.

Zitieren

APA

Cai, A., She, Z., Lv, J., Zhou, X., & Xie, M. (2026). MicroRNA-138-2-3p inhibits cell migration, invasion and EMT process in non-small-cell lung cancer by targeting antizyme inhibitor 1. Revista de Investigación Clínica. https://doi.org/10.1016/j.ric.2025.100032

Vancouver

Cai A, She Z, Lv J, Zhou X, Xie M. MicroRNA-138-2-3p inhibits cell migration, invasion and EMT process in non-small-cell lung cancer by targeting antizyme inhibitor 1. Revista de Investigación Clínica. 2026. doi:10.1016/j.ric.2025.100032

BibTeX
@article{Cai2026,
  author = {Cai, Ang and She, Zhuocui and Lv, Jun and Zhou, Xiaokang and Xie, Miaomiao},
  title = {MicroRNA-138-2-3p inhibits cell migration, invasion and EMT process in non-small-cell lung cancer by targeting antizyme inhibitor 1},
  journal = {Revista de Investigación Clínica},
  year = {2026},
  doi = {10.1016/j.ric.2025.100032}
}
Kostenlos starten →